Prognostic Factors and Role of Postoperative Radiotherapy in Surgically Resected Thymomas

Overview

Journal JTCVS Open

Specialty Cardiology & Vascular Diseases

Date 2023 Jul 10

PMID 37425431

Authors

Fujun Yang

Jie Dai

Xiaoying Lou

Bin Zhou

Kaiqi Jin

Qiuyuan Li

Nan Song

Deping Zhao

Yuming Zhu

Haifeng Wang

Gening Jiang

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the prognostic factors in and role of postoperative radiotherapy (PORT) for surgically resected thymomas.

Methods: A total of 1540 patients with pathologically confirmed thymomas undergoing resection between 2000 and 2018 were identified retrospectively from the SEER (Surveillance, Epidemiology, and End Results) database. Tumors were restaged as local (limited to thymus), regional (invasion to mediastinal fat and other neighboring structures), or distant stage. Disease-specific survival (DSS) and overall survival (OS) were estimated by the Kaplan-Meier method and the log-rank test. Adjusted hazard ratios (HRs) with 95% CIs were calculated by Cox proportional hazards modeling.

Results: Tumor stage and histology were independent predictors of both DSS (regional: HR, 3.711; 95% CI, 2.006-6.864; distant: HR, 7.920; 95% CI, 4.061-15.446; type B2/B3: HR, 1.435; 95% CI, 1.008-2.044) and OS (regional: HR, 1.461; 95% CI, 1.139-1.875; distant: HR, 2.551; 95% CI, 1.855-3.509; type B2/B3: HR, 1.409; 95% CI, 1.153-1.723). For patients with regional stage and type B2/B3 thymomas, PORT was associated with better DSS after thymectomy/thymomectomy (HR, 0.268; 95% CI, 0.099-0.727), but the association was not significant after extended thymectomy (HR, 1.514; 95% CI, 0.516-4.44). Among patients with lymph node metastases, those who received PORT (HR, 0.372; 95% CI, 0.146-0.949), chemotherapy (HR, 0.843; 95% CI, 0.303-2.346), or both (HR, 0.296, 95% CI, 0.071-1.236) had a better OS.

Conclusions: The extent of invasion and tumor histology were independent predictors of worse survival following surgical resection of thymoma. Patients with regional invasion and type B2/B3 thymoma who undergo thymectomy/thymomectomy may benefit from PORT, while patients with nodal metastases may benefit from multimodal therapy, including PORT and chemotherapy.

Citing Articles

Perspectives on surgical treatment for thymic epithelial tumors: a narrative review.

Nabe Y, Inoue M, Yoshida J Gland Surg. 2024; 13(2):225-235.

PMID: 38455346 PMC: 10915418. DOI: 10.21037/gs-23-453.

References

Fang W, Wang Y, Pang L, Gu Z, Wei Y, Liu Y . Lymph node metastasis in thymic malignancies: A Chinese multicenter prospective observational study. J Thorac Cardiovasc Surg. 2018; 156(2):824-833.e1. DOI: 10.1016/j.jtcvs.2018.04.049. View

Nakagawa K, Yokoi K, Nakajima J, Tanaka F, Maniwa Y, Suzuki M . Is Thymomectomy Alone Appropriate for Stage I (T1N0M0) Thymoma? Results of a Propensity-Score Analysis. Ann Thorac Surg. 2015; 101(2):520-6. DOI: 10.1016/j.athoracsur.2015.07.084. View

Liu Q, Gu Z, Yang F, Fu J, Shen Y, Wei Y . The role of postoperative radiotherapy for stage I/II/III thymic tumor-results of the ChART retrospective database. J Thorac Dis. 2016; 8(4):687-95. PMC: 4824725. DOI: 10.21037/jtd.2016.03.28. View

Imbimbo M, Ottaviano M, Vitali M, Fabbri A, Leuzzi G, Fiore M . Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME). Cancer Treat Rev. 2018; 71:76-87. DOI: 10.1016/j.ctrv.2018.10.001. View

Marchevsky A, Gupta R, Mckenna R, Wick M, Moran C, Zakowski M . Evidence-based pathology and the pathologic evaluation of thymomas: the World Health Organization classification can be simplified into only 3 categories other than thymic carcinoma. Cancer. 2008; 112(12):2780-8. DOI: 10.1002/cncr.23492. View

Liu H, Gu Z, Qiu B, Detterbeck F, Roden A, Ruffini E . A Recurrence Predictive Model for Thymic Tumors and Its Implication for Postoperative Management: a Chinese Alliance for Research in Thymomas Database Study. J Thorac Oncol. 2019; 15(3):448-456. DOI: 10.1016/j.jtho.2019.10.018. View

Kondo K, Monden Y . Lymphogenous and hematogenous metastasis of thymic epithelial tumors. Ann Thorac Surg. 2003; 76(6):1859-64. DOI: 10.1016/s0003-4975(03)01017-8. View

Hwang Y, Park I, Park S, Kim E, Kang C, Kim Y . Lymph Node Dissection in Thymic Malignancies: Implication of the ITMIG Lymph Node Map, TNM Stage Classification, and Recommendations. J Thorac Oncol. 2016; 11(1):108-14. DOI: 10.1016/j.jtho.2015.09.001. View

Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S . Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5:v40-55. DOI: 10.1093/annonc/mdv277. View

10.

Meurgey A, Girard N, Merveilleux du Vignaux C, Maury J, Tronc F, Thivolet-Bejui F . Assessment of the ITMIG Statement on the WHO Histological Classification and of the Eighth TNM Staging of Thymic Epithelial Tumors of a Series of 188 Thymic Epithelial Tumors. J Thorac Oncol. 2017; 12(10):1571-1581. DOI: 10.1016/j.jtho.2017.06.072. View

11.

Gao L, Wang C, Fang W, Zhang J, Lv C, Fu S . Outcome of multimodality treatment for 188 cases of type B3 thymoma. J Thorac Oncol. 2014; 8(10):1329-34. DOI: 10.1097/JTO.0b013e31829ceb50. View

12.

Omasa M, Date H, Sozu T, Sato T, Nagai K, Yokoi K . Postoperative radiotherapy is effective for thymic carcinoma but not for thymoma in stage II and III thymic epithelial tumors: the Japanese Association for Research on the Thymus Database Study. Cancer. 2015; 121(7):1008-16. DOI: 10.1002/cncr.29166. View

13.

Rimner A, Yao X, Huang J, Antonicelli A, Ahmad U, Korst R . Postoperative Radiation Therapy Is Associated with Longer Overall Survival in Completely Resected Stage II and III Thymoma-An Analysis of the International Thymic Malignancies Interest Group Retrospective Database. J Thorac Oncol. 2016; 11(10):1785-92. PMC: 5257334. DOI: 10.1016/j.jtho.2016.06.011. View

14.

Rice T, Ishwaran H, Ferguson M, Blackstone E, Goldstraw P . Cancer of the Esophagus and Esophagogastric Junction: An Eighth Edition Staging Primer. J Thorac Oncol. 2016; 12(1):36-42. PMC: 5591443. DOI: 10.1016/j.jtho.2016.10.016. View

15.

Falkson C, Bezjak A, Darling G, Gregg R, Malthaner R, Maziak D . The management of thymoma: a systematic review and practice guideline. J Thorac Oncol. 2009; 4(7):911-9. DOI: 10.1097/jto.0b013e3181a4b8e0. View

16.

Weksler B, Shende M, Nason K, Gallagher A, Ferson P, Pennathur A . The role of adjuvant radiation therapy for resected stage III thymoma: a population-based study. Ann Thorac Surg. 2012; 93(6):1822-8. DOI: 10.1016/j.athoracsur.2012.03.004. View

17.

Moon J, Lee K, Shin M, Kim S, Woo S, Lee G . Thymic epithelial tumors: prognostic determinants among clinical, histopathologic, and computed tomography findings. Ann Thorac Surg. 2014; 99(2):462-70. DOI: 10.1016/j.athoracsur.2014.09.050. View

18.

Marx A, Chan J, Coindre J, Detterbeck F, Girard N, Harris N . The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes. J Thorac Oncol. 2015; 10(10):1383-95. PMC: 4581965. DOI: 10.1097/JTO.0000000000000654. View

19.

Clermidy H, Maury J, Collaud S, Drevet G, Ginoux M, Chalabreysse L . Lymph Node Dissection in Thymoma: Is it worth it?. Lung Cancer. 2021; 157:156-162. DOI: 10.1016/j.lungcan.2021.05.022. View

20.

Harnath T, Marx A, Strobel P, Bolke E, Willers R, Gripp S . Thymoma-a clinico-pathological long-term study with emphasis on histology and adjuvant radiotherapy dose. J Thorac Oncol. 2012; 7(12):1867-1871. DOI: 10.1097/JTO.0b013e3182745f73. View